Navigation Links
Nektar Therapeutics Reports First Quarter 2009 Financial Results
Date:5/6/2009

usiness, results of operations and financial condition could suffer; and (vi) certain other important risks and uncertainties set forth in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2009 and the company's most recent Quarterly Report on Form 10-Q to be filed on or about May 8, 2009. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

    Jennifer Ruddock, 650-631-4954
    Nektar Therapeutics

    Susan Noonan, (212) 966-3650
    SAN Group

                        NEKTAR THERAPEUTICS
          CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
           (In thousands, except per share information)
                            (unaudited)

                                                  Three-Months
                                                 Ended March 31,
                                                -----------------
                                                  2009      2008
                                                  ----      ----
    Revenue:
       Product sales and royalties               $6,470   $10,371
       Collaboration and other                    3,241     9,621
                                                  -----     -----
    Total revenue                                 9,711    19,992

    Operating costs and expenses:
       Cost of goods sold                         5,099     7,227
       Other cost of revenue                          -     5,334
       Research and development                  23,890    37,373
       General and administrative                11,020    11,947
                                                 ------    ------
    Total operating cos
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... a primary focus on the continued rapid development ... workforce reduction,of 52 employees, representing approximately 33% of ... Endo Pharmaceuticals, Inc. have agreed to,mutually terminate their ...
... enterprise accounting system across its US & China-based ... Alternext US: ADL), a vertically integrated pharmaceutical company ... today it is implementing a state-of-the-art, westernized enterprise ... , , Developed by ...
... Amicus Therapeutics (Nasdaq: FOLD ) will announce ... the regular close of markets on Thursday, February 5, ... live conference call and webcast that afternoon at 5 ... conference call at 5 p.m. EST by dialing 877-675-4756 ...
Cached Biology Technology:Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation 2Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation 3Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation 4AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 2AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 3AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 4Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date 2
(Date:4/23/2014)... ravens form different types of social relationships they ... form strict dominance relations. From a cognitive perspective, understanding ... in daily social life ("knowing who is nice or ... with each other sets the stage for "political" maneuvers ... study have been published in the scientific journal ...
(Date:4/23/2014)... can argue that if we were to follow a strong ... canthen we can solve the climate problem without doing geoengineering." ... researchers, in the current issue of Bulletin of the ... action on climate change now makes it more likely that ... explains in an exclusive Bulletin interview. , ...
(Date:4/22/2014)... a five-year, $3 million study to determine whether an ... of dissolved organic matter (DOM) through the Connecticut River ... composition and water quality of the watershed and Long ... Foundation,s MacroSystems Biology program, researchers will collect data from ... Canada and runs through five U.S. states, before emptying ...
Breaking Biology News(10 mins):Ravens understand the relations among others 2Is nuclear power the only way to avoid geoengineering? 2Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3
... Society of Interventional Radiology, an international organization of ... improving public health through minimally invasive, image-guided treatments, ... Veins" coalition, an alliance of organizations united to ... veins and chronic venous insufficiency. "Becoming part ...
... and deaths linked to those products are fostering new ... to the cover story in the current edition of ... of the American Chemical Society, the world,s largest scientific society. ... stories have surfaced with increasing frequency in recent years about ...
... the cross-country ski run. Things are looking good for him. Up ... best time. However, whether or not he finishes first is often ... must be right, including the conditions on the cross-country ski run, ... adapted custom-fit skis. In contrast to Olympic skiing stars who are ...
Cached Biology News:Society of Interventional Radiology: Time to rethink varicose veins 2Optimized custom-made ski sledges 2Optimized custom-made ski sledges 3
7G10 anti-Fasciclin III...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Goat polyclonal to HA1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: TLGSCRERQPEFV from the C terminus of human HA1. Entrez GeneID: 23526 Swiss Protein ID: O78181...
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Biology Products: